bioMérieux, a world leader in the field of in vitro diagnostics, has launched NucliSENS EasyQ MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections (HAIs).
The new test rapidly detects seven MRSA types, covering the most prevalent strains, with a turnaround time of less than three hours and the flexibility for batch (46 tests) or stand alone (1 test) screening.
With simultaneous detection of two targets, the NucliSENS EasyQ System reduces the risk of false positive results, improves specificity, and avoids re-testing and inappropriate antibiotic treatment or isolation of patients. NucliSENS EasyQ MRSA is CE marked and more molecular tests for resistant bacteria, like VRE and C. difficile, are planned for the platform in the future. Influenza A/B, HIV viral load, HSV 1+2 and RSV A+B are among the tests already available.
“bioMérieux is actively driving the fight against HAIs by getting the right information to clinicians quickly with our molecular solution EasyQ MRSA,” said Stéphane Bancel, bioMérieux Chief Executive Officer.
“At a time when reducing healthcare costs is paramount, we are proud to bring an automated molecular test that we are launching at an attractive price.”
